Corlanor Approval History
- FDA approved: Yes (First approved April 15th, 2015)
- Brand name: Corlanor
- Generic name: ivabradine
- Dosage form: Tablets
- Company: Amgen Inc.
- Treatment for: Heart Failure
Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated for the treatment of chronic heart failure.
Development History and FDA Approval Process for Corlanor
|Apr 15, 2015||FDA Approves Corlanor (ivabradine) to Treat Heart Failure|
|Aug 27, 2014||FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.